Roche receives CE Mark for VENTANA FOLR1 RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

Roche Denmark Finland France Germany Netherlands Sweden United Kingdom Arizona

The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FR?), which is over-expressed in most ovarian cancers.View original content:https://www.prnewswire.co.uk/news-releases/roche-receives-ce-mark-for-ventana-folr1-folr1-2-1-rxdx-assay-as-the-first-ihc-based-companion-diagnostic-to-identify-ovarian-cancer-patients-eligible-for-elahere-302307489.html